(E)-3-[2-(4-Fluoro-phenyl)-2,4,5,6,7,8-hexahydro-cycloheptapyrazol-3-yl]-propenal | 144149-58-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (E)-3-[2-(4-Fluoro-phenyl)-2,4,5,6,7,8-hexahydro-cycloheptapyrazol-3-yl]-propenal
• 英文别名: (E)-3-[2-(4-fluorophenyl)-5,6,7,8-tetrahydro-4H-cyclohepta[c]pyrazol-3-yl]prop-2-enal
• CAS: 144149-58-6
• 化学式: C₁₇H₁₇FN₂O
• 分子量: 284.333
• InChiKey: HLFFLSONDAXRCL-QPJJXVBHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.49
• 重原子数：
  21.0
• 可旋转键数：
  3.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  34.89
• 氢给体数：
  0.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  (E)-3-[2-(4-Fluoro-phenyl)-2,4,5,6,7,8-hexahydro-cycloheptapyrazol-3-yl]-propenal 在 sodium hydroxide 、 sodium tetrahydroborate 、 air 、 三乙基硼 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 3.0h， 生成 Sodium; (E)-(3S,5R)-7-[2-(4-fluoro-phenyl)-2,4,5,6,7,8-hexahydro-cycloheptapyrazol-3-yl]-3,5-dihydroxy-hept-6-enoate
  参考文献：
  名称：

  HMG-CoA reductase inhibitors: design, synthesis, and biological activity of tetrahydroindazole-substituted 3,5-dihydroxy-6-heptenoic acid sodium salts

  摘要：

  Compounds comprising a series of 7-[2-(4-fluorophenyl)-4,5,6,7-tetrahydro-2H-indazol-3-yl]-3,5-dihydroxy-6-heptenoic acid sodium salts (18) were synthesized and tested for their ability to inhibit HMG-CoA reductase in a partially purified enzyme preparation and cholesterol biosynthesis from acetate in cultured HEP-G2 cells. Changing the size of the saturated ring of the tetrahydroindazole nucleus did not improve potency, but incorporation of substituents at the 7-position resulted in up to 1700-fold improvement in inhibitory potency. Structure-activity studies revealed that the most potent compounds possess a substituted benzyl group at the 7-position, with a preference for steric bulk at the para position of the benzene ring. The most potent enzyme inhibitor (18t, IC50 = 3.0 nM) is approximately 3-fold more potent than lovastatin sodium salt (2). The most potent cholesterol biosynthesis inhibitor in HEP-G2 cells (18q, IC50 = 0.078 muM) is slightly less potent than 2 (sodium salt). Molecular modeling studies suggested that, when compared to the parent compound (18b) lacking the appropriate 7-substituent, 18t overlaps better with 2 and literature inhibitors 5 and 6 in a hydrophobic binding region adjacent to the enzyme active site.

  DOI：

  10.1021/jm00075a024
• 作为产物：
  描述：

  2-(4-fluorophenyl)-2,4,5,6,7,8-hexahydrocycloheptapyrazole-3-carboxaldehyde 在 manganese(IV) oxide 、 sodium hydride 、 二异丁基氢化铝 作用下， 以 四氢呋喃 、 甲苯 、 苯 为溶剂， 反应 2.5h， 生成 (E)-3-[2-(4-Fluoro-phenyl)-2,4,5,6,7,8-hexahydro-cycloheptapyrazol-3-yl]-propenal
  参考文献：
  名称：

  HMG-CoA reductase inhibitors: design, synthesis, and biological activity of tetrahydroindazole-substituted 3,5-dihydroxy-6-heptenoic acid sodium salts

  摘要：

  Compounds comprising a series of 7-[2-(4-fluorophenyl)-4,5,6,7-tetrahydro-2H-indazol-3-yl]-3,5-dihydroxy-6-heptenoic acid sodium salts (18) were synthesized and tested for their ability to inhibit HMG-CoA reductase in a partially purified enzyme preparation and cholesterol biosynthesis from acetate in cultured HEP-G2 cells. Changing the size of the saturated ring of the tetrahydroindazole nucleus did not improve potency, but incorporation of substituents at the 7-position resulted in up to 1700-fold improvement in inhibitory potency. Structure-activity studies revealed that the most potent compounds possess a substituted benzyl group at the 7-position, with a preference for steric bulk at the para position of the benzene ring. The most potent enzyme inhibitor (18t, IC50 = 3.0 nM) is approximately 3-fold more potent than lovastatin sodium salt (2). The most potent cholesterol biosynthesis inhibitor in HEP-G2 cells (18q, IC50 = 0.078 muM) is slightly less potent than 2 (sodium salt). Molecular modeling studies suggested that, when compared to the parent compound (18b) lacking the appropriate 7-substituent, 18t overlaps better with 2 and literature inhibitors 5 and 6 in a hydrophobic binding region adjacent to the enzyme active site.

  DOI：

  10.1021/jm00075a024